TGA approves Feraccru to treat iron deficiency in Australia.- Shield Therapeutics + Norgine

Shield Therapeutics plc , a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer (ferric maltol), notes that Australia’s Therapeutics Goods Administration has registered Feraccru in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults. Feraccru is already approved in the UK, European Union, Switzerland and United States for the treatment of iron deficiency with or without anaemia in adults. Norgine Pty Ltd will lead all marketing activities in Australia. The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for medicinal products.